Physician profile
Alison Stratton
NPI 1407638414
$5,352.93
in general payments reported to CMS, 2019-2025
41 companies · $3,336 in 2025
The $3,336 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $689 · 2024: $1,328 · 2025: $3,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,972 · Long Term Medical Supply Or Device Loan: $1,180 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,971.86 |
| Long Term Medical Supply Or Device Loan | $1,180.03 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,980.85 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $424.99 | 2023-2025 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $284.24 | 2024-2025 | Rybrevant, Carvykti, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $203.08 | 2024-2025 | Opdivo, Opdualag |
| Abbvie INC. | $172.45 | 2024-2025 | |
| Daiichi Sankyo INC. | $168.66 | 2024-2025 | Enhertu, Vanflyta |
| Pharmacosmos Therapeutics INC. | $164.54 | 2024 | Monoferric |
| Pfizer INC. | $153.20 | 2024-2025 | |
| Seagen INC. | $150.77 | 2023 | Tukysa, Padcev, Adcetris |
| Astrazeneca Pharmaceuticals LP | $144.51 | 2023-2025 | Calquence |
| Ipsen Biopharmaceuticals, INC | $141.51 | 2025 | Onivyde |
| Pharmaessentia USA Corporation | $125.00 | 2025 | Besremi |
| Beone Medicines USA, INC. | $120.79 | 2025 | Brukinsa |
| Amgen INC. | $113.01 | 2023 | |
| Novo Nordisk INC | $104.43 | 2024 | Wegovy |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $81.14 | 2024-2025 | Pomalyst, Opdivo, Reblozyl |
| Array Biopharma INC | $79.65 | 2023-2025 | Mektovi, Braftovi, Tukysa |
| Lilly USA, LLC | $71.38 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $49.69 | 2024-2025 | |
| Kite Pharma, INC. | $46.79 | 2025 | Yescarta |
| Eisai INC. | $45.43 | 2024-2025 | |
| Genentech USA, INC. | $43.18 | 2023-2025 | Polivy, Columvi, Lunsumio |
| Exelixis INC. | $39.87 | 2023-2025 | Cabometyx |
| Sumitomo Pharma America, INC. | $35.60 | 2024-2025 | Orgovyx |
| Astellas Pharma US INC | $34.47 | 2024 | Xtandi |
| Genzyme Corporation | $30.58 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.76 | 2025 | Fruzaqla |
| Tersera Therapeutics LLC | $28.19 | 2025 | Quzyttir |
| Mirati Therapeutics, INC. | $28.13 | 2023-2024 | Krazati |
| Verity Pharmaceuticals INC. | $25.07 | 2025 | Trelstar |
| Pharmaand Gmbh | $24.36 | 2025 | Rubraca |
| Tolmar, INC. | $24.36 | 2025 | Eligard, Rubraca |
| Geron Corporation | $22.82 | 2025 | Rytelo |
| Jazz Pharmaceuticals INC. | $21.37 | 2023 | |
| Acrotech Biopharma INC. | $19.88 | 2023 | Beleodaq |
| Aveo Pharmaceuticals, INC. | $19.70 | 2023 | Fotivda |
| Puma Biotechnology, INC. | $17.94 | 2025 | |
| Taiho Oncology, INC. | $17.76 | 2025 | |
| Glaxosmithkline, LLC. | $17.41 | 2025 | Ojjaara |
| Blueprint Medicines Corporation | $14.97 | 2023 | Ayvakit |
| Beigene USA, INC. | $14.35 | 2025 | Tevimbra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Stratton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.